A phase 2 study to evaluate the safety and immunogenicity of a recombinant hiv type 1 vaccine based on adeno-associated virus

AIDS Research and Human Retroviruses

Volumn 26, Issue 8, 2010, Pages 933-942

  Vardas, Eftyhia ^a   Kaleebu, Pontiano ^b,c   Bekker, Linda Gail ^d   Hoosen, Anwar ^e   Chomba, Elwyn ^f   Johnson, Philip R ^g   Anklesaria, Pervin ^h   Birungi, Josephine ^b   Barin, Burc ⁱ   Boaz, Mark ^j   Cox, Josephine ^j   Lehrman, Jennifer ^j   Stevens, Gwynn ^k   Gilmour, Jill ^j   Tarragona, Tony ^j   Hayes, Peter ^j   Lowenbein, Sarah ^j   Kizito, Eva ^j   Fast, Patricia ^j   Heald, Alison E ^h   Schmidt, Claudia ^j   more..

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

^d Institute of Infectious Disease and Molecular Medicine   (South Africa)

^e SEFAKO MAKGATHO HEALTH SCIENCES UNIVERSITY   (South Africa)

^f EMORY UNIVERSITY   (United States)

^g CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^h Targeted Genetics Corporation   (United States)

ⁱ EMMES CORPORATION   (United States)

^j INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^k IAVI Southern Africa   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; PARVOVIRUS VECTOR; PLACEBO; RECOMBINANT VACCINE; TGAAC09 VACCINE; UNCLASSIFIED DRUG; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOGENICITY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION; VOLUNTEER; ANTIBODY PRODUCTION; BLOOD; DEPENDOPARVOVIRUS; GENE VECTOR; HIV INFECTIONS; IMMUNIZATION; IMMUNOLOGY; MIDDLE AGED; T LYMPHOCYTE; VIROLOGY; YOUNG ADULT;

ADULT; AIDS VACCINES; ANTIBODIES, NEUTRALIZING; ANTIBODY FORMATION; DEPENDOVIRUS; DOUBLE-BLIND METHOD; FEMALE; GENETIC VECTORS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION SCHEDULE; MALE; MIDDLE AGED; T-LYMPHOCYTES; VACCINES, SYNTHETIC; YOUNG ADULT;

EID: 77955638013     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0242     Document Type: Article

References (11)

1. Carter BJ, Burstein H, and Peluso RW: Adeno-associated virus and AAV vectors for gene delivery. In: Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, 3rd ed. (Templeton NS, ed.). CRC Press, Boca Raton, FL, 2009, pp. 115-157.
2. Calcedo R, Vandenberghe LH, Gao G, Lin J, and Wilson JM: Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis 2009;199:381-390.
3. Schnepp BC, Clark KR, Klemanski DL, Pacak CA, and Johnson PR: Genetic fate of recombinant adeno-associated virus vector genomes in muscle. J Virol 2003;77:3495-3504.
4. Schnepp BC, Jensen RL, Chen CL, Johnson PR, and Clark KR: Characterization of adeno-associated virus genomes isolated from human tissues. J Virol 2005;79:14793-14803.
5. Johnson PR, Schnepp BC, Connell MJ, et al.: Novel adenoassociated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques. J Virol 2005;79: 955-965.
6. Mehendale S, Clumeck N, Rockstroh J, et al.: A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV-1 subtype C adeno-associated virus vaccine. AIDS Res Hum Retroviruses 2008;24:873-880.
7. Good Clinical Laboratory Practice (GCLP): A quality system for laboratories which undertake the analyses of samplesfrom clinical trials. BARQA, 2003. (Accessed at http:// www.barqa.com.)
8. Atkinson EM, Debelak DJ, Hart LA, and Reynolds TC: A high-throughput hybridization method for titer determination of viruses and gene therapy vectors. Nucleic Acids Res 1998;26:2821-2823.
9. Boaz MJ, Hayes P, Tarragona T, et al.: Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents. Clin Vaccine Immunol 2009;16:147-155.
10. Peters BS, Jaoko W, Vardas E, et al.: Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: Effects of dosage and route on safety and immunogenicity. Vaccine 2007;25(11):2120-2127.
11. Karita E, Ketter N, Price M, et al.: CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa. PloS One 2009;4, Issue 2.